Dr. Byrd on Impact of Ibrutinib on Patients With CLL

John C. Byrd, MD
Published: Wednesday, Sep 06, 2017



John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Ohio State University have had to add a survivorship clinic to their institution due to the number of patients who have participated in ibrutinib clinical trials, including RESONATE. Moreover, Byrd explains, many of these patients would likely not have survived if they did not receive treatment with ibrutinib.

Hearing patients' stories and seeing them continue to live life magnifies the effect of ibrutinib on patients with CLL, he adds.


John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Ohio State University have had to add a survivorship clinic to their institution due to the number of patients who have participated in ibrutinib clinical trials, including RESONATE. Moreover, Byrd explains, many of these patients would likely not have survived if they did not receive treatment with ibrutinib.

Hearing patients' stories and seeing them continue to live life magnifies the effect of ibrutinib on patients with CLL, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x